SPDR S&P Biotech ETF
Price through Oct 2 · Flows through Oct 1. Figures use the latest available records, not a live quote. Fund details retrieved Oct 3. Holdings snapshot retrieved Oct 3.
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 1M SHOWN · NET −$658M OVER THIS RANGE
Money is leaving — −$658M in net outflows over the past month, about 6.5% of the fund's asset base, while the price has returned +26.7% so far this year. At 0.35% a year it is not the cheapest way in — AVIE has a reported fee of 0.25%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | MRNAMODERNA | 1.41% | $190.01 | +0.6% | ||
| 2 | TWSTTWIST BIOSCIENCE | 1.40% | $188.67 | +0.3% | ||
| 3 | IOVAIOVANCE BIOTHERAPEUTICS | 0.56% | $14.21 | -0.1% | ||
| 4 | GRALGRAIL INC | 0.90% | $143.26 | +8.1% | ||
| 5 | NTRANATERA | 1.16% | $410.35 | +0.5% | ||
| 6 | HALOHALOZYME THERAPEUTICS | 1.03% | $109.86 | +2.7% | ||
| 7 | RVMDREVOLUTION MEDICINES | 1.20% | $206.64 | +0.4% | ||
| 8 | KODKODIAK SCIENCES | 0.54% | $94.45 | -4.1% | ||
| 9 | KYMRKYMERA THERAPEUTICS | 1.35% | $107.39 | -2.5% | ||
| 10 | PTGXPROTAGONIST THERAPEUTICS | 1.07% | $140.06 | +0.6% | ||
| 11 | ORKAOruka Therapeutics | 1.37% | $84.52 | +1.3% | ||
| 12 | IBRXIMMUNITYBIO | 1.02% | $10.29 | +10.8% | ||
| 13 | ROIVROIVANT SCIENCES | 1.15% | $35.72 | +0.6% | ||
| 14 | SMMTSUMMIT THERAPEUTICS | 1.01% | $16.75 | +0.4% | ||
| 15 | PCVXVAXCYTE | 1.18% | $56.48 | +0.8% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 135| 1 week | -0.4% |
| 1 month | -6.1% |
| 3 months | -3.8% |
| 6 months | +20.1% |
| YTD | +26.7% |
| 1 year | +49.1% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | −$88M |
| 1 month | −$658M |
| 3 months | −$396M |
| YTD | +$219M |
| 1 year | +$775M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 1.5% of the book; the top ten carry 13%. Spread across 151+ names, it behaves like roughly 110 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $24M | $31M |
| ABBV ABBVIE | $4M | $5M |
| IOVA IOVANCE BIOTHERAPEUTICS | $4M | $4M |
| IBRX IMMUNITYBIO | $4M | $3M |
| VKTX VIKING THERAPEUTICS | $2M | $4M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat XBI on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41.5B | +$286M | -32bp on fee · 4× the assets · +$286M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.2B | +$199M | -32bp on fee · 2× the assets · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.9B | +$497M | -31bp on fee · 3× the assets · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.7B | +$575M | -31bp on fee · 2× the assets · +$575M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -31bp on fee · 2× the assets · +$412M in over the month | Head-to-head |